Combination antiretroviral therapy accelerates immune recovery in patients with HIV-related lymphoma treated with EPOCH: a comparison within one prospective trial AMC034

References

• Little RF, Gutierrez M, Jaffe ES, et al. HIV-associated non-Hodgkin lymphoma: incidence, presentation, and prognosis. JAMA. 2001;285:1880–1885.
   PubMed Web of Science ®Google Scholar
• Long JL, Engels EA, Moore RD, et al. Incidence and outcomes of malignancy in the HAART era in an urban cohort of HIV-infected individuals. AIDS 2008;22:489–496.
   PubMed Web of Science ®Google Scholar
• Bohlius J, Schmidlin K, Costagliola D, et al. Incidence and risk factors of HIV-related non-Hodgkin's lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009;14:1065–1074.
   PubMed Web of Science ®Google Scholar
• Levine AM, Wernz JC, Kaplan L, et al. Low-dose chemotherapy with central nervous system prophylaxis and zidovudine maintenance in AIDS-related lymphoma. A prospective multi-institutional trial. JAMA. 1991;266:84–88.
   PubMed Web of Science ®Google Scholar
• Straus DJ, Huang J, Testa MA, et al. Prognostic factors in the treatment of human immunodeficiency virus-associated non-Hodgkin’s lymphoma: analysis of AIDS Clinical Trials Group protocol 142–low-dose versus standard-dose m-BACOD plus granulocyte-macrophage colony-stimulating factor. National Institute of Allergy and Infectious Diseases. J Clin Oncol 1998;16:3601–3606.
   PubMed Web of Science ®Google Scholar
• Noy A. Update in HIV lymphoma. Curr Opin Oncol. 2006;18:449–455.
   PubMed Web of Science ®Google Scholar
• Sparano JA. HIV-associated lymphoma: the evidence for treating aggressively but with caution. Curr Opin Oncol. 2007;19:458–463.
   PubMed Web of Science ®Google Scholar
• Levine AM. HIV-associated lymphoma. Blood. 2010;115:2986–2987.
   PubMed Web of Science ®Google Scholar
• Oriol A, Ribera JM, Esteve J, et al. Lack of influence of human immunodeficiency virus infection status in the response to therapy and survival of adult patients with mature B-cell lymphoma or leukemia. Results of the PETHEMA-LAL3/97 study. Haematologica. 2003;88:445–453.
   PubMed Web of Science ®Google Scholar
• Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol. 2008;140:411–419.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Bruno Ventre M, Donadoni G, et al. Safety and activity of a new intensive short-term chemoimmunotherapy in HIV-positive patients with Burkitt lymphoma. Br J Haematol. 2012;159:252–255.
   PubMed Web of Science ®Google Scholar
• Coutinho R, Pria AD, Gandhi S, et al. HIV status does not impair the outcome of patients diagnosed with diffuse large B-cell lymphoma treated with R-CHOP in the cART era. Aids. 2014;28:689–697.
   PubMed Web of Science ®Google Scholar
• Dunleavy K, Wilson WH. How I treat HIV-associated lymphoma. Blood 2012;119:3245–3255.
   PubMed Web of Science ®Google Scholar
• Little RF, Dunleavy K. Update on the treatment of HIV-associated hematologic malignancies. Hematol Am Soc Hematol Educ Program. 2013;2013:382–388.
   PubMedGoogle Scholar
• Barta SK, Xue X, Wang D, et al. Treatment factors affecting outcomes in HIV-associated non-Hodgkin lymphomas: a pooled analysis of 1546 patients. Blood. 2013;122:3251–3262.
   PubMed Web of Science ®Google Scholar
• Sparano JA, Lee JY, Kaplan LD, et al. Rituximab plus concurrent infusional EPOCH chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma. Blood. 2010;115:3008–3016.
   PubMed Web of Science ®Google Scholar
• Pharm GKB. The pharmacogenetics and pharmacogenomics knowledge base – doxorubicin pathway, pharmacokinetics. 2016. [cited 2016 March 04]. Available from: https://www.pharmgkb.org/pathway/PA165292177
   Google Scholar
• Pharm GKB. Doxorubicin pathways: pharmacodynamics and adverse effects [Internet]. 2010. Available from: https://www.pharmgkb.org/pathway/PA165292177
   Google Scholar
• Etoposide Pathway [Internet]. 2011. Available from: https://www.pharmgkb.org/pathway/PA2025
   Google Scholar
• Pharm GKB. The pharmacogenetics and pharmacogenomics knowledge base – etoposide pathway, pharmacokinetics/pharmacodynamics. 2011. Available from: https://www.pharmgkb.org/pathway/PA2025
   Google Scholar
• Whirl-Carrillo M, McDonagh EM, Hebert JM, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther. 2012;92:414–417.
   PubMed Web of Science ®Google Scholar
• Pharm GKB. The pharmacogenetics and pharmacogenomics knowledge base – vinka alkaloid pathway, pharmacokinetics. 2011. Available from: https://www.pharmgkb.org/pathway/PA150981002
   Google Scholar
• Mackall CL, Fleisher TA, Brown MR, et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994;84:2221–2228.
   PubMed Web of Science ®Google Scholar
• Hakim FT, Cepeda R, Kaimei S, et al. Constraints on CD4 recovery postchemotherapy in adults: thymic insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood. 1997;90:3789–3798.
   PubMed Web of Science ®Google Scholar
• Powles T, Imami N, Nelson M, et al. Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. AIDS. 2002;16:531–536.
   PubMed Web of Science ®Google Scholar
• Bower M, Stebbing J, Tuthill M, et al. Immunologic recovery in survivors following chemotherapy for AIDS-related non-Hodgkin lymphoma. Blood. 2008;111:3986–3990.
   PubMed Web of Science ®Google Scholar
• Little RF, Pittaluga S, Grant N, et al. Highly effective treatment of acquired immunodeficiency syndrome-related lymphoma with dose-adjusted EPOCH: impact of antiretroviral therapy suspension and tumor biology. Blood. 2003;101:4653–4659.
   PubMed Web of Science ®Google Scholar
• Zanussi S, Simonelli C, D’Andrea M, et al. The effects of antineoplastic chemotherapy on HIV disease. AIDS Res Hum Retroviruses. 1996;12:1703–1707.
   PubMed Web of Science ®Google Scholar
• Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer. 2006;106:1560–1568.
   PubMed Web of Science ®Google Scholar
• Antinori A, Cingolani A, Alba L, et al. Better response to chemotherapy and prolonged survival in AIDS-related lymphomas responding to highly active antiretroviral therapy. AIDS. 2001;15:1483–1491.
   PubMed Web of Science ®Google Scholar
• Sinha S, Shekhar RC, Singh G, et al. Early versus delayed initiation of antiretroviral therapy for Indian HIV-Infected individuals with tuberculosis on antituberculosis treatment. BMC Infect Dis. 2012;12:168.
   PubMed Web of Science ®Google Scholar
• Shao HJ, Crump JA, Ramadhani HO, et al. Early versus delayed fixed dose combination abacavir/lamivudine/zidovudine in patients with HIV and tuberculosis in Tanzania. AIDS Res Hum Retroviruses. 2009;25:1277–1285.
   PubMed Web of Science ®Google Scholar
• Cruciani M, Gatti G, Vaccher E, et al. Pharmacokinetic interaction between chemotherapy for non-Hodgkin's lymphoma and protease inhibitors in HIV-1-infected patients. J Antimicrob Chemother. 2005;55:546–549.
   PubMed Web of Science ®Google Scholar
• El-Sadr WM, Lundgren J, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283–2296.
   PubMed Web of Science ®Google Scholar
• Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795–807.
   PubMed Web of Science ®Google Scholar
• Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol. 2001;19:2171–2178.
   PubMed Web of Science ®Google Scholar
• Vaccher E, Spina M, di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer. 2001;91:155–163.
   PubMed Web of Science ®Google Scholar
• Kaplan LD, Straus DJ, Testa MA, et al. Low-dose compared with standard-dose m-BACOD chemotherapy for non-Hodgkin's lymphoma associated with human immunodeficiency virus infection. National Institute of Allergy and Infectious Diseases AIDS Clinical Trials Group. N Engl J Med. 1997;336:1641–1648.
   PubMed Web of Science ®Google Scholar
• Barta SK, Lee JY, Kaplan LD, et al. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012;118:3977–3983.
   PubMed Web of Science ®Google Scholar
• Churchill D, Waters L, Ahmed N, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2015. HIV Med. 2016;17(Suppl 4):s2–s104.
   PubMed Web of Science ®Google Scholar